Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TLN-254
- Development stage
- Phase 1
- Lead developer
- Treeline Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TLN-254 is an investigational oral small molecule drug being developed for the treatment of relapsed or refractory T-cell lymphomas, including peripheral T-cell lymphoma (PTCL), anaplastic large cell lymphoma (ALCL), cutaneous T-cell lymphoma (including Sezary syndrome and mycosis fungoides), follicular lymphoma, immunoblastic lymphadenopathy, and other related neoplasms. The drug is currently in Phase 1 clinical trials to determine its safety, optimal dosing, and anti-tumor activity in these patient populations. TLN-254 is administered as a tablet by mouth. It is being developed using artificial intelligence and machine learning technology platforms by Treeline Biosciences.
Beyond the preview
Go deeper on TLN-254.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLN-254.